Clinical Trial Update: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for RGN-259 ophthalmic solutions in dry eye syndrome, reporting safety and efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndrome

Drugs mentioned

• RGN-259 ophthalmic solutions (RGN-259 ophthalmic solution)

Snippet

Sponsor: ReGenTree, LLC | Conditions: Dry Eye Syndromes, Dry Eye | Phase 3 | Status: COMPLETED